Pharsight

Prialt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5795864 TERSERA Stable omega conopetide formulations
Jun, 2015

(8 years ago)

US5364842 TERSERA Method of producing analgesia
Dec, 2016

(7 years ago)

US9707270 TERSERA Method for administering ω-conopeptide
Oct, 2024

(4 months from now)

US8653033 TERSERA Method for administering omega-conopeptide
Oct, 2024

(4 months from now)

US8765680 TERSERA Method for administering omega-conopeptide
Oct, 2024

(4 months from now)

Prialt is owned by Tersera.

Prialt contains Ziconotide Acetate.

Prialt has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Prialt are:

  • US5795864
  • US5364842

Prialt was authorised for market use on 28 December, 2004.

Prialt is available in injectable;intrathecal dosage forms.

Prialt can be used as analgesia, treatment of pain, treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine.

The generics of Prialt are possible to be released after 01 October, 2024.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Market Authorisation Date: 28 December, 2004

Treatment: Analgesia; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Treatment of pain

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage

PRIALT family patents

Family Patents